 Leukemia, Myeloid
"Leukemia, Myeloid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Descriptor ID |
D007951
|
| MeSH Number(s) |
C04.557.337.539
|
| Concept/Terms |
Leukemia, Myeloid- Leukemia, Myeloid
- Leukemia, Granulocytic
- Myeloid Leukemia
- Leukemias, Myeloid
- Myeloid Leukemias
- Leukemia, Myelogenous
- Leukemias, Myelogenous
- Myelogenous Leukemias
- Myelocytic Leukemia
- Myelogenous Leukemia
- Granulocytic Leukemia
- Granulocytic Leukemias
- Leukemias, Granulocytic
- Leukemia, Myelocytic
- Leukemias, Myelocytic
- Myelocytic Leukemias
Leukemia, Monocytic, Chronic- Leukemia, Monocytic, Chronic
- Monocytic Leukemia, Chronic
- Chronic Monocytic Leukemia
- Chronic Monocytic Leukemias
- Leukemia, Chronic Monocytic
- Leukemias, Chronic Monocytic
- Monocytic Leukemias, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid".
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia, Myelomonocytic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Sarcoma, Myeloid
This graph shows the total number of publications written about "Leukemia, Myeloid" by people in this website by year, and whether "Leukemia, Myeloid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myeloid" by people in Profiles.
-
Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola S, Brodersen L, Loken M, Tong S, Druley T, O'Brien M, Hijiya N, Heerema-McKenney A, Wang YC, Schore R, Taub J, Gamis A, Kolb EA, Berman JN. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021 12 09; 138(23):2337-2346.
-
Lamba JK, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, Meshinchi S, Loken MR. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leuk Lymphoma. 2018 09; 59(9):2250-2253.
-
Gerbing RB, Alonzo TA, Sung L, Gamis AS, Meshinchi S, Plon SE, Bertuch AA, Gramatges MM. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. J Clin Oncol. 2016 11 01; 34(31):3766-3772.
-
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2015 10 20; 8:115.
-
Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. Cancer Genet. 2015 Jul-Aug; 208(7-8):408-13.
-
Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 2012 Oct 01; 118(19):4806-14.
-
Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011 Dec 22; 118(26):6752-9; quiz 6996.
-
Norton A, Fisher C, Liu H, Wen Q, Mundschau G, Fuster JL, Hasle H, Zeller B, Webb DK, O'Marcaigh A, Sorrell A, Hilden J, Gamis A, Crispino JD, Vyas P. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007 Aug 01; 110(3):1077-9.
-
Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review. Pediatr Blood Cancer. 2005 Jan; 44(1):13-20.
-
Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003 Sep 15; 21(18):3415-22.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|